What Prostalin Treats: Main Uses and Benefits

Prostalin is commonly used to help with symptom clusters related to physical discomfort and resultant functional strain, generally focusing on conditions involving episodic or fluctuating manifestations like severe, chronic vascular conditions. This application is relevant in clinical settings that involve acute or disruptive symptom patterns, such as pulmonary arterial hypertension.

Prostalin may be part of symptomatic management relevant in conditions involving episodic or fluctuating manifestations like Pulmonary Arterial Hypertension (PAH), Chronic Arterial Occlusive Disease (CAOD), and related ischemic conditions. It is used for managing the distressing symptoms, providing supportive therapeutic benefit to patients experiencing rest pain, intermittent claudication, and significant exercise intolerance. This symptomatic assistance supports general well-being during symptomatic phases.

“The primary goal of this supportive medication is to ease the overall symptom load and assist with maintaining functional stability in the context of chronic circulatory deficits.”

Quick Fact: Relief for Ischemic Symptoms

Prostalin is commonly used to help with symptom clusters that may become intense, such as the pain associated with a lack of adequate blood supply, and assists with managing the symptoms related to ischemic ulcers and lesions in the extremities. This supportive action is considered relevant when the symptoms linked to poor circulation create noticeable physiological strain.

Eligibility Map: Who can and cannot use Prostalin (Beraprost Sodium) — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label):	Adult patients (typically 18 years and older) with the specific circulatory conditions for which the medicine is indicated.
Populations for whom use is not recommended (if applicable):	Patients with severe renal impairment. The pediatric population. Females who are breastfeeding.
Populations for whom use is contraindicated:	Patients with known hypersensitivity to Beraprost sodium. Patients with active major bleeding or hemorrhagic conditions. Patients with severe hepatic impairment. Females who are pregnant.

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification (as defined in official documents):	Contraindicated, Not Recommended, Use with Caution, Not Established (for pediatric use).
Regulatory basis (EMA / FDA / etc.):	Government-approved Prescribing Information defining Contraindications and Use in Specific Populations.
Eligibility-context constraints (as defined in official documents):	Constraints are based on the drug's inherent antiplatelet and vasodilatory properties.

---

Resulting Eligibility Structure

Official eligibility statements:

• Use is formally contraindicated in patients with active hemorrhage.
• The medicine is contraindicated in patients with severe hepatic impairment.
• The use during pregnancy is officially not recommended or contraindicated.

Connection to the overall eligibility profile: The official regulatory documents define the eligible population as adults without active bleeding or severe organ failure. Non-eligibility is established through strict contraindications against conditions that significantly compound the drug's inherent antiplatelet and vasodilatory risks, ensuring use is confined to populations where the safety profile has been formally assessed.

Interactions with other medicines and products

This section documents the official interaction patterns for Prostalin (Beraprost sodium) as described in regulatory labeling.

Interaction Scope

Category	Official Regulatory Information
Interacting Medicine Categories	Antiplatelet Agents, Anticoagulants, Vasodilators, Antihypertensive Agents, Strong CYP3A4 Inhibitors, Strong CYP3A4 Inducers.
Specific Interacting Substances	Warfarin, Aspirin, Grapefruit juice (non-medicinal product).
Interaction-Related Restrictions	Co-administration is formally noted as requiring caution with strong CYP3A4 inhibitors, including grapefruit juice.
Population-Specific Note	The medicine is officially contraindicated or requires extreme caution in the presence of severe hepatic or renal impairment due to the documented risk of reduced drug clearance.

Interaction Classifications

The interaction profile is structured by effects on the body's systems or metabolism.

Classification Type	Official Regulatory Statement
Interaction Severity	Interactions are classified as carrying a documented Increased risk of bleeding or Additive hypotensive effects.
Interaction-Context Constraints	Disease-state constraint requiring official precaution in the setting of severe hepatic or renal impairment.

Resulting Interaction Structure

Official statements define two primary risks: a synergistic effect with antiplatelet agents and anticoagulants that increases the risk of bleeding, and an additive effect with vasodilators that may cause an increased drop in blood pressure. The official pharmacokinetic profile states that strong CYP3A4 inhibitors elevate Beraprost exposure, while inducers reduce it. These constraints govern the official use of the medicine.

Prostalin is a proprietary name associated with two distinct drug substances, Alprostadil or Prostalene, both synthetic Prostaglandin analogs, though their mechanisms target different physiological systems depending on the intended use.

As an Alprostadil analog, it acts as an agonist at specific prostaglandin receptors, primarily the EP2 receptor (a G-protein coupled receptor). Receptor binding activates the intracellular enzyme adenylate cyclase. This activation catalyzes the conversion of ATP to 3',5'-cyclic adenosine monophosphate (cAMP), leading to a rise in the intracellular concentration of cAMP. The increase in cAMP modulates downstream signaling pathways, triggering the dephosphorylation of myosin light chain within vascular and corpus cavernosum smooth muscle cells. This cascade results in smooth muscle cell relaxation and subsequent vasodilation, which modulates localized blood flow in targeted tissues. Prostaglandin analogs also modulate immune cell activity and inhibit platelet aggregation via similar cAMP-mediated mechanisms.

Prostalin (Beraprost sodium) is administered by the oral route as a tablet. Standard clinical protocols establish specific dosing and scheduling requirements that govern its proper use.

---

Labeled Dosing Regimens

The standard dosage and frequency are determined by the specific condition being addressed. For chronic arterial occlusion (CAOD), the regimen involves administering 40 mu g per dose. When used for primary pulmonary hypertension (PAH), treatment typically begins with a lower starting dose of 20 mu g per dose. The dose for PAH is subject to gradual adjustment (titration) based on the patient's condition, with the total amount divided into administrations that should not exceed a maximum daily limit of 180 mu g.

---

Frequency, Timing, and Administration Rules

The medicine is generally scheduled to be taken three times a day (TID). A critical instruction for administration is the requirement to take the tablets after meals, establishing a time-relationship concept tied to proper intake. If a dose is missed, standard instructions specify that the missed dose must be skipped entirely; the subsequent dose must be taken according to the regular schedule, and two doses must not be taken at one time to compensate.

---

Special Procedural Conditions

The protocol for PAH treatment requires that the total daily dosage may be divided into three to four separate administrations during the titration phase. Patients with renal impairment may require careful administration and dose adjustments due to potential changes in drug clearance. Safety and efficacy for use in pediatric patients have not been well-established.

Research Evidence / Overview of Studies for Prostalin

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research examined Prostalin (Beraprost sodium) for its use in patients with Pulmonary Arterial Hypertension, a condition characterized by high blood pressure in the arteries of the lungs. The research focused on adults with functional limitations, specifically those in WHO functional class II or III. The main studies conducted were short-term to intermediate-term randomized, double-blind, placebo-controlled trials where patients were monitored in a controlled setting.

The outcomes that research examined included objective measures of physical capability, such as the Six-Minute Walk Distance (6MWD). Studies also monitored the time until patients experienced a defined composite endpoint of disease progression. Findings describe patterns observed in the studies where initial functional measurements were reported in the group receiving the study medicine in the short term. However, research highlights patterns where these functional measurements did not consistently persist when patients were monitored in longer follow-up periods.

Evidence for use in Chronic Arterial Occlusive Disease (CAOD) / Intermittent Claudication

The research examined Prostalin in patients with Chronic Arterial Occlusive Disease (CAOD), particularly those experiencing Intermittent Claudication (IC)—pain or cramping in the legs that occurs with exercise. The evidence mainly comes from randomized, placebo-controlled trials used in research exploring how symptoms change over time. These studies primarily included adult patients diagnosed with claudication.

The main outcomes reflecting daily functioning or activity level that research examined were the distance a patient could walk on a treadmill before experiencing pain (Pain-Free Walking Distance or PFWD) and the distance they could walk at maximum effort (Maximum Walking Distance or MWD). Findings were mixed across different large trials concerning these objective walking measurements. While some intermediate-term studies described a measurement pattern in the PFWD outcome, others indicated inconsistent patterns in either PFWD or MWD when compared to the control group.

Studies on Durability and Extended Follow-up

Most of the primary clinical evidence for Prostalin comes from studies where follow-up durations were limited, typically lasting less than six months. In the research settings for PAH, research exploring short-term symptom changes was observed in multiple trials, but these studies often noted that any initial changes did not persist when patients were monitored in the longer, open-label extension phases. This highlights a key area where long-term effects are not fully established for maintaining functional measurements.

Research in Special Populations

The research primarily includes adult patient populations; however, Prostalin was studied for use in pediatric populations in the context of PAH. Specific, specialized trials research examined how symptoms and functional markers change in children with PAH. The results apply only to the populations studied in these specific pediatric settings. Limited information is available from controlled trials specifically examining outcomes for older adults as a distinct subgroup, particularly those with multiple co-existing conditions.

What is Still Uncertain About Prostalin Research

A major uncertainty relates to the findings were mixed across major controlled trials, especially in the context of CAOD, where the objective walking distance outcomes was not uniformly observed. Another key gap is the limited information for long-term outcomes across both primary indications. While research describes short-term patterns, the persistence of these changes and the effects over many years are not fully characterized by high-quality RCTs. The evidence quality varies across studies, and the lack of strong, consistent comparative evidence makes contextualizing the findings within the broader evidence landscape an ongoing scientific challenge.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification B01AC19 (Beraprost)

Common questions about Prostalin (FAQ)

---

Q: What is the main difference between Prostalin and other common treatments for the same condition?

Prostalin contains the active substance Beraprost sodium, which is classified as a prostacyclin analogue. According to official documents, this substance is the first derivative of prostacyclin that is suitable for oral administration. This distinguishing feature sets it apart from certain other prostanoid medicines that may require intravenous (IV) delivery.

---

Q: How quickly should I expect to notice anything after starting Prostalin?

Information from research studies indicates that the monitoring of the medicine’s effects on physical capability and functional markers has typically been assessed within the first 6 to 12 weeks of treatment. This time frame reflects when functional changes were observed and recorded.

---

Q: How long do most patients use Prostalin for?

Official research summaries state that the primary evidence supporting the medicine’s use comes from short-term studies. Information regarding the persistence of functional measurements over a long-term duration is not fully characterized by the core research.

---

Q: Does Prostalin affect liver function?

Official product information notes that administration constraints are required in the presence of severe hepatic impairment (severe liver issues). This is due to the documented risk of altered drug clearance in these specific health conditions.

---

Q: How does the official information address use in patients with kidney issues?

Regulatory documentation notes that patients with renal impairment (kidney issues) may require careful administration. This is because official documents require that dose adjustments be considered due to altered drug clearance, which affects how the body processes the medicine.

---

Q: What is the typical timeframe for maximum effect of Prostalin?

The timeframe for reaching the maximum observed change is typically assessed in research settings. Clinical studies have historically monitored the primary measures of physical capability to assess changes at the 6- and 12-week time points to gauge initial response.

---

Q: What objective measures did research studies examine when assessing the medicine's effects?

Research studies describe examining changes in objective measures of physical capability. These include how far a patient can walk without pain (Pain-Free Walking Distance) or the Six-Minute Walk Distance, which were the functional outcomes monitored in research studies.

---

Q: Are the side effects of Prostalin temporary or permanent?

Official documents describe many common effects, such as headache and flushing, as often being dose-dependent and transient (temporary). These effects may be more noticeable when treatment begins or when the dose is changed.

---

Q: Is Prostalin a type of antibiotic?

No, Prostalin is not an antibiotic. It is officially classified as a Prostacyclin analogue and a Platelet aggregation inhibitor, which means it works by affecting the circulatory system.

---

Q: Can women or people assigned female at birth use Prostalin?

Regulatory authorities generally apply constraints or advise caution regarding the use of the medicine during both pregnancy and breastfeeding. Specific instructions and considerations should be reviewed in the official documentation for these populations.

---

Q: Will Prostalin interfere with my ability to drive or operate machinery?

Official side effect information lists dizziness and hypotension (low blood pressure) as common adverse reactions. These types of effects may potentially interfere with the ability to drive or operate machinery.

---

Q: Are there any specific monitoring requirements while using Prostalin (e.g., blood tests)?

Official documents state that administration and dose adjustments are required for patients with renal or hepatic impairment. The need for dose adjustments in these conditions is a constraint noted in official documentation.

---

Q: Is there any research on Prostalin use in younger adults?

Research has primarily included adult patient populations in its studies. Specialized trials have also examined the use of the medicine in pediatric populations (children).

---

Q: What is the difference between brand-name Prostalin and a generic version?

Prostalin contains the single active substance, Beraprost sodium. A generic version of the medicine would contain the identical active substance, as required by regulatory standards.

Official Storage and Disposal Requirements

Detail	Regulatory Requirement
Temperature	Store at room temperature, specifically below 30 C; do not refrigerate or freeze.
Handling & Packaging	Must be kept in the original container and protected from light and moisture.
Child Safety	Store out of the sight and reach of children.
Disposal	Dispose of unused medicinal product or waste material in accordance with local requirements.
Environmental Rule	The medicine must not be disposed of via wastewater or household waste.

Official regulatory documents define the mandatory storage conditions to ensure product stability, requiring storage below 30 C and protection from both light and moisture in the original container. The tablets must remain out of the reach of children. Disposal is subject to local pharmaceutical waste regulations, with an explicit rule against discarding the product via household waste or by flushing it into the wastewater system.